Homepage > Company > Media > Pharma News > 2022 > Moderna Projects $21 Billion Annual Revenue for Its COVID-19 Vaccine

Moderna Projects $21 Billion Annual Revenue for Its COVID-19 Vaccine

Moderna said it expects to earn approximately $21 billion from sales of its COVID-19 vaccine, Spikevax, this year, based on its advance purchase agreements. The previous estimate was $19 billion.

The projected revenue could also increase if the vaccine is no longer being offered for free in the U.S. through federally funded programs. Congress is currently considering whether to allocate more funding for federal COVID-19 vaccination programs.

Spikevax is the Cambridge, Mass.-based company’s first approved messenger RNA (mRNA) product. The company is expanding its mRNA vaccine program to include several other viruses.

March 28, 2022

https://www.fdanews.com/

Read also

Ventus and Genentech

Ventus and Genentech partner for small-molecule medicine discovery

Aspire Pharma’s

Acquisition strengthens Aspire Pharma’s strategic portfolio

Alkermes to acquire Avadel for $2.1bn

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.

NanoViricides

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies